Yanrong Hao

Statistics

Publications

Citations

364

H-Index

Active since

2022

Affiliations

The People's Hospital of Guangxi Zhuang Autonomous Region(Current)

China Medical University

Nantong Tumor Hospital

Beijing Chest Hospital

Second Affiliated Hospital of Anhui Medical University

Yanrong Hao is an author at The People's Hospital of Guangxi Zhuang Autonomous Region specializing in medicine, pharmacology, and egfr mutation testing.

ORCID

Publications per year

2022–2024

Publications

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

Yuankai Shi, Gongyan Chen, Xiang Wang et al. · The Lancet Respiratory Medicine · 2022 · 230 citations

Medicine, Oncology, Pharmacology +13

Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study

Yuankai Shi, Gongyan Chen, Xiang Wang et al. · Journal of Thoracic Oncology · 2022 · 77 citations

Medicine, Neurology, Pharmacology +6

Peripheral changes in T cells predict efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer

Juanfeng Lao, Huiting Xu, Zibin Liang et al. · Immunobiology · 2023 · 46 citations · Full text

Medicine, Immunology, Oncology +17

Prognostic nomogram based on pre-treatment HALP score for patients with advanced non-small cell lung cancer

Shan Gao, Qin Huang, Suosu Wei et al. · Clinics · 2024 · 11 citations · Full text

Medicine, Oncology, Chemotherapy +14

1–4 of 4